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ABSTRACT
Idiopathic pulmonary fibrosis (IPF) is a chronic
progressive disease of unknown aetiology. It has a very
poor prognosis and no effective treatment. There are two
major barriers to the development of novel treatments in
IPF: an incomplete understanding of its pathogenesis and
the fact that current models of the disease are poorly
predictive of therapeutic response. Recent studies
suggest an important role for the alveolar epithelium in
the pathogenesis of IPF. However, practical limitations
associated with isolation and culture of primary alveolar
epithelial cells have hampered progress towards further
elucidating their role in the pathogenesis of the disease
or developing disease models that accurately reflect the
epithelial contribution. The practical limitations of primary
alveolar epithelial cell culture can be divided into
technical, logistical and regulatory hurdles that need to
be overcome to ensure rapid progress towards improved
treatment for patients with IPF. To develop a strategy to
facilitate alveolar epithelial cell harvest, retrieval and
sharing between IPF research groups and to determine
how these cells contribute to IPF, a workshop was
organised to discuss the central issues surrounding
epithelial cells in IPF (ECIPF). The central themes
discussed in the workshop have been compiled as the
proceedings of the ECIPF.
INTRODUCTION
Idiopathic pulmonary fibrosis (IPF) is a chronic
progressive disease of unknown aetiology. The
incidence of IPF has more than doubled in the UK
in the last 15 years with approximately 5000 new
cases each year.1 These incidence rates are higher
than many cancers including renal, pelvic and
haematological malignancies. Likewise, the prog-
nosis of IPF is as grave as many tumours with
5-year survival rates of 43%2 and a median survival
of 2.4 years.3 No treatment has been found to be
effective in altering the prognosis of the disease.4e6
Thus, IPF is a chronic, incurable and progressively
fatal disease.
There are two major barriers to the development
of novel effective therapies for IPF. First, there is
incomplete understanding of the pathogenesis of
the disease. The current paradigm suggests that,
following repeated subclinical injury to the lung,
there is epithelial damage with subsequent
destruction of the alveolar-capillary basement
membrane. This permits fibrogenic cell infiltration
of the alveolar interstitium, with activation of
fibroblasts leading to the generation of the highly
contractile synthetic a-smooth muscle actin-
positive myofibroblast which is considered to be
the key effector cell in pulmonary fibrosis.7 8 The
alveolus is composed of alveolar type I and II (ATII)
epithelial cells that adhere to the alveolar-capillary
basement membrane. Following injury, normal
wound healing requires that an intact epithelium
be restored swiftly to re-establish barrier integrity
and prevent excess mesenchymal activation and
accumulation. This requires spatially and tempo-
rally coordinated responses leading to formation of
a provisional matrix along which activated myofi-
broblasts migrate, promoting wound contraction.
Epithelial cells migrate over the basal layer to
regenerate the damaged area of lung before cellular
debris and provisional matrix are remodelled and
removed. In IPF the lung epithelium has several
pathological features including hyperplasia of ATII,
the presence of transitional epithelial cells,
with areas of bronchiolisation and squamous
metaplasia.9e11 The integrity of the basement
membrane is disrupted with hyperplastic ATII cell
proliferation on an inappropriate extracellular
matrix, with failure of restoration of normal alve-
olar structures.12 Furthermore, in lung fibrosis there
is upregulation of epithelial-associated molecules
involved in repair and development including
integrins and components of the WNT signalling
pathway.13e15 However, it is unknown whether
these pathological changes of the epithelium are
primary abnormalities or are a response to injury
and whether they lead to the deposition of disor-
dered matrix.
Second, current models of lung fibrosis do not
reliably predict the clinical response to novel
therapies. These model systems focus mainly on
single-cell culture systems or animal models.
Animal models have generated significant insights,
especially when combined with data from human
tissue.16e20 However, it has to be stated that all in
vivo models rely, to some extent, on inducing injury
in otherwise healthy lungs, whether by over-
expressing transforming growth factor b (TGF-b),
instilling bleomycin, FITC, silica or vanadium, or
exposing the animal to thoracic irradiation. Further
understanding the role of epithelial cells in IPF is
limited due to the poor availability of primary lung
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epithelial cells which are believed to play a crucial role in the
disease process. Most of the work defining the pathogenesis of
IPF has therefore been performed on epithelial cell lines derived
from tumours or immortalised cells. The value of using malig-
nant cells in such studies is unclear and alternative options
include the use of rodent epithelial cells. There are certainly
advantages to the use of rodent cells, including the logistical
advantages of obtaining primary cells to order, the disease and
treatment-free nature of the cells, the defined genetic back-
ground and the natural history of these cells. However, there are
also limitations such as low yields of murine epithelilal cells,
considerable variation among mouse strains and the relative lack
of reagents for use in the rat to date.
Owing to the hurdles described, it is difficult to answer key
questions such as whether enhanced injury promotes persisting
epithelial damage or whether epithelial damage results from an
abnormal epithelial response to injury. Similarly, we do not
know if there is an intrinsic epithelial defect promoting fibrosis,
or even whether targeting the epithelium will be a useful ther-
apeutic strategy. Thus, the analysis and characterisation of the
human alveolar epithelium, which in IPF is likely to have an
intrinsic failure of wound repair, is indispensable and will
undoubtedly shed further light on our understanding of IPF.
To overcome these barriers and to develop effective novel
treatments, an improved supply of primary diseased and control
alveolar lung epithelial cells is required. With well-phenotyped
well-characterised primary human alveolar epithelial cells,
meaningful comparative biology experiments can be performed.
Furthermore, such cells could be used to develop 2D and 3D in
vitro systems that may better predict the therapeutic response
of IPF to novel treatments. However, to develop a usable supply
of diseased primary epithelial cells, there are a number of hurdles
that need to be overcome including biological, technical, logis-
tical, ethical and regulatory barriers. All of these hurdles will
require a nationallydor even internationallydcoordinated
approach to cell harvesting. A workshop on lung epithelial
biology was therefore held on 15 October 2010 to determine
a consensus approach to studying, harvesting and distributing
primary alveolar epithelial cells throughout the UK which, in
turn, could be used internationally.
EPITHELIAL CELL BIOLOGY IN IPF
The role of the alveolar epithelium in IPF is poorly understood
due, in large part, to technical limitations in obtaining primary
alveolar epithelial cells from patients with lung fibrosis. At
present many studies use cell lines and surrogates such as A549
adenocarcinoma cells to generate and test hypotheses relating to
the role of alveolar epithelial cells in IPF.21 Similarly, many
groups use commercial sources of airway epithelial cells or
rodent alveolar epithelial cells to investigate normal lung
epithelial cell biology. Given the absence of data defining what
constitutes a ‘fibrotic’ epithelial cell, it is important not to be too
dogmatic about the initial approaches to studying IPF-related
epithelial cell biology. While the cell lines may be suitable for
initial exploratory IPF studies, data derived from such cells must
acknowledge the limitations associated with these tools (eg, the
clonal disruption of TGF-b signalling pathways in tumour cells).
Replication of key findings in primary cells must always be
established before these data can be considered representative. A
further challenge for researchers is the fact that there are no
lineage tracing experiments that can conclude, with certainty,
the origin of the hyperplastic epithelial cells that are character-
istic of fibrotic lung. There are sufficient data demonstrating
that both the large and small airways are abnormal in IPF to
support the use of epithelial cells derived from the distal airway
in initial hypothesis-generating experiments.22e25 While the use
of such distal airway epithelial cells might be reasonable for
studying generic lung epithelial pathways, it is probably not
appropriate to use these cells as controls for comparative biology
experiments with diseased ATII cells from IPF lungs.
The major challenges of using primary ATII cells relate to
viability and fragility (they rarely survive freezing), limited
replicative capacity when cultured, purity (lack of consistent
markers and mesenchymal cell ‘contamination’ in disease states)
and their tendency to acquire features of type I alveolar cells
when cultured.26 How this might affect the key pathological
pathways in IPF is unknown, but systematic phenotyping of
epithelial cells from all regions of the lung and from freshly
isolated lung epithelial cells prior to culture would help answer
this fundamental question. As with all cell culture systems,
tissue culture artefact is also a concern, but this may be mini-
mised by culturing primary cells on Matrigel, in 2D or 3D co-
culture systems, culturing cells at the air-liquid interface and
limiting the time in in vitro cell culture to ensure study of
phenotypically relevant cells, but substrate-specific phenotypes
are always likely to occur.27 Similarly, it is important to validate
data obtained from mechanistic cell culture experiments to
demonstrate that cell culture data may be representative of the
disease. Techniques such as laser capture microdissection and
immunohistochemistry can be used to augment in vitro data
and overcome some cell culture limitations, but such studies are
hampered by the ability to obtain appropriate control tissue for
laser capture studies and the observational subjective nature of
immunohistochemistry.
OBTAINING LUNG EPITHELIAL CELLS FROM FIBROTIC LUNG
TISSUE
Currently there are three potential sources of lung tissue for the
investigation of IPF: spare tissue from diagnostic clinical samples
obtained from video-assisted thoracoscopic surgery (VATS) lung
biopsies, lung from postmortem examination or explanted
tissue following lung transplant surgery. There are significant
drawbacks with each source.
VATS biopsies are usually performed when the diagnosis of
IPF is unclear and in a younger population with a higher likeli-
hood of having a diagnosis other than IPF. Furthermore, the yield
of cells obtained from the ‘spare’ tissue is insufficient for
meaningful studies. To obtain enough epithelial cells for in vitro
culture experiments, a whole lobe needs to be processed.
Explanted tissue is therefore necessary, but this can only be
obtained from people with advanced fibrotic lung that yields
fewer epithelial cells. Furthermore, there is concern that
processes active in end-stage architecturally-remodelled fibrotic
lung might not represent the pathobiology of early disease and
may no longer be amenable to therapeutic manipulation.
The isolation of rodent type II cells was first described in 1974
by Kikkawa and Yoneda,28 and the protocol has since been
adapted to isolate type II cells from a number of species
including rodents, rabbits and humans.29 They all involve
proteolytic (elastase, dispase and/or trypsin) digestion and many
utilise density gradient separation and negative selection.
Robinson et al were the first to isolate human type II cells in
1984 using a similar protocol.30 In normal human lung this
approach can yield at least 13106 cells/g of lung tissue, which
are 95% pure ATII cells.31 32 Modifications of this method have
been described to yield higher purities (up to 98%) of human
ATII cells using different enzymes and positive selection by flow
cytometry,27 antibody-coated magnetic beads33 or differential
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adherence.34 The cells should be characterised by at least two
epithelial markers, including Sp-C and E-cadherin, to determine
cell purity. Cells obtained from fibrotic lung using the latter
protocol, however, are often contaminated, with only approxi-
mately 80% exhibiting classic ATII cell characteristics.35
Whether this is contamination with fibroblasts characteristic of
IPF or represents nascent epithelial-to-mesenchymal transition
remains to be determined. Flow Activated Cell Sorting (FACS)
can be used to increase the purity of fibrotic epithelial cells, but
at a vastly reduced yield (2e8 million/right middle lobe vs 160
million/right middle lobe). Furthermore, whether FACS leads to
loss of the more diseased epithelial cells remains a concern.
Finally, alveolar epithelial cell viability is dramatically reduced
following freezing, thus making long-term storage of these cells
impossible. Transportation and transfer of the cells between
laboratories is therefore more challenging than with many other
cell types.
LOGISTICS OF PRIMARY ALVEOLAR EPITHELIAL CELL BIOLOGY
To study primary alveolar epithelial cells in IPF, a whole lobe
should be digested and the cells harvested within 48 h of
removal from the patient. Ideally, experiments should be
performed on the cells within 7 days of harvest in order to
preserve their pathological phenotype and limit change in
culture. The whole middle lobe could be obtained from post-
mortem specimens harvested rapidly following death,36 but
requires ante mortem identification and consent as well as rapid
mobilisation of pathology departments. Practically, in the
current UK environment, this could only be realistically
considered for patients who die in hospital during office hours.
The most reliable source of IPF epithelial cells is therefore
from explanted lungs harvested at the time of lung trans-
plantation. However, there are only five lung transplant centres
in the UK and only a small number of transplanted patients
have IPF. Indeed, in 2008 only 157 patients with IPF received
a lung transplant in the whole of the EU (population 500
million) compared with 516 in the USA (population 300
million). Furthermore, not all UK lung transplant centres have
IPF research programmes and many IPF researchers do not work
in transplant centres, so there is considerable wastage of
potential research tissue. These limitations are further exacer-
bated by the challenging nature of harvesting diseased primary
cells. Therefore, even where IPF researchers operate in transplant
centres, explanted disease tissue will be wasted if the researchers
cannot experiment on them immediately.
It is abundantly clear that explanted IPF tissue is a highly
valuable research tool and, as such, it should not be wasted.
However, at present in the UK and, to a large extent, within the
EU, systems are not in place to maximise explanted tissue
retrieval. Crucially, successful epithelial cell harvest can occur up
to 48 h after the lung has been removed from the patient if the
lung is stored at 48C. Thus, the opportunity exists to develop
a system that is responsive to the needs of the organ retrieval
teams and researchers, permitting epithelial biology experiments
throughout the UK. However, it will require a coordinated
national approach to be successful.
GOVERNANCE AND REGULATION
The Human Tissue Act 2004 (HTA) laid down a framework for
tissue storage and transfer, and it has placed consent firmly at
the centre of all tissue-focused research. It also provided defini-
tions and codes of practice to which all researchers must adhere.
Since the Act became active on 1 September 2006 there has been
a marked increase in procedural bureaucracy and not a little
confusion. However, it has led to an improvement in archiving
and curating tissue samples throughout the UK which, in turn,
encourages and facilitates tissue sharing. The HTA has created
an environment whereby organisations and institutions are
looking to improve their regulatory and governance frameworks
in a coordinated fashion owing to the nationwide implementa-
tion of the Act (with the exception of Scotland). Now is
therefore the time to ensure that generic consent, tissue transfer
agreements, research ethics approval as well as the standardised
operating procedures for clinical phenotyping, tissue retrieval,
harvest and storage are coordinated around UK centres to facil-
itate nationwide distribution of explanted diseased lung tissues.
CONCLUSION
Given the absence of a clear understanding of the pathogenesis
of IPF, the lack of primary cells for comparative biology experi-
ments and the disappointing failure to translate experimental
data into viable treatments, the slow progress in developing
therapies for treating IPF is hardly surprising. If novel effective
treatments are to be developed, improving the tools to study the
disease is a necessity. There is therefore an urgent need to
develop mechanisms for harvesting and distributing primary
epithelial cells from patients with IPF and controls.
Human tissue is an altruistic gift from patients to the research
community, given in the hope that others may benefit from the
research performed on their tissues. Thus, diseased as well as
control tissue samples are an incredibly valuable resource
because of the information that can be gained from their study
and also because of the circumstances of their generation.
Because of the scarcity of the tissue and its processing limita-
tions, this value is amplified in IPF. It is therefore crucial that
diseased lung tissue is not wasted.
To ensure maximal benefit from explanted disease tissue, it is
essential that a network is established that is responsive to organ
retrieval and researchers’ requirements, thus enabling tissue to
be obtained when available and distributed where it can be
productively used at any given time. The basic requirements of
this responsive network will include generic consent, biobanking
facilities, core technical services, agreed standardised operating
procedures, agreed access and governance procedures and logis-
tical strategies. This will require a significant investment of time
and resources, but there is no doubting the value of such a
systemdor the collective willdto implement such a process.
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